Single-dose Preoperative Partial Breast Irradiation in Low-risk Breast Cancer Patients

In this ABLATIVE-2 trial, low-risk breast cancer patients will be treated with MRI-guided single dose preoperative partial breast radiotherapy to assess the rate of pathologic complete response after an interval of six to twelve months between radiotherapy and surgery. Response monitoring will be assessed using MRI and markers in blood and tumor tissue to enable prediction of pathologic response.

Trial Details

NCT ID
NCT05350722
Phase
NA
Sponsor
Amsterdam UMC, location VUmc
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Single dose ablative radiotherapy
Locations (sample)
  • Sydney, Australia|-33.86785,151.20732
  • Almere Stad, Netherlands|52.37025,5.21413
  • Amstelveen, Netherlands|52.30083,4.86389
  • Amsterdam, Netherlands|52.37403,4.88969
  • Nijmegen, Netherlands|51.8425,5.85278

Key Eligibility Criteria

  • WHO performance scale ≤2.
  • Females at least 50 years of age with unifocal cT1N0 breast cancer on mammography, ultrasound and MRI.
  • Patients with an indication for chemotherapy or HER2-targeted therapy according to Dutch National Oncoline Guidelines or own hospital protocols are…
  • Tumor size as assessed on MRI.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →